Evidence map›Paper›PMID 33352710›Full record

ArticleJournal of clinical medicine2020

The Tryptophan System in Cocaine-Induced Depression.

Francina Fonseca, Joan-Ignasi Mestre-Pintó, Àlex Gómez-Gómez, Diana Martinez-Sanvisens, Rocío Rodríguez-Minguela, Esther Papaseit, Clara Pérez-Mañá, Klaus Langohr, Olga Valverde, Óscar J Pozo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Tryptophan and Substance Abuse: Mechanisms and Impact.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Francina FonsecaAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-0779-6545
Joan-Ignasi Mestre-PintóAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0003-0387-9375
Àlex Gómez-GómezDepartment of Experimental and Health Sciences (CEXS), Universitat Pompeu Fabra, 08002 Barcelona, Spain.
Diana Martinez-SanvisensInstitut de Neuropsiquiatria i Addiccions, Hospital del Mar, 08003 Barcelona, Spain.
Rocío Rodríguez-MinguelaAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Esther PapaseitDepartment of Psychiatry and Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona (UAB), 08290 Cerdanyola del Vallès, Spain.
Clara Pérez-MañáDepartment of Psychiatry and Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona (UAB), 08290 Cerdanyola del Vallès, Spain.ORCID 0000-0001-6343-6918
Klaus LangohrIntegrative Pharmacology and Systems Neuroscience Research Group, Neuroscience Research Programme, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Olga ValverdeNeurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08002 Barcelona, Spain.ORCID 0000-0003-2264-7852
Óscar J PozoIntegrative Pharmacology and Systems Neuroscience Research Group, Neuroscience Research Programme, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Magí FarréDepartment of Psychiatry and Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona (UAB), 08290 Cerdanyola del Vallès, Spain.ORCID 0000-0001-8338-7543
Marta TorrensAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0001-6222-4761
On Behalf Of Neurodep Group
Universitat Autònoma de Barcelona · ESHospital Del Mar · ESUniversitat Pompeu Fabra · ES

Funding

IMPACT OF TS PROPHYLAXIS ON ANTIFOLATE RESISTANT MALARIAK01TW000014 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI KUBLIN, JAMES G. · 2000 to 2000
$103k
Acció instrumental d'Intensificació de Professionals de la Salut - Facultatius especialistes (PERIS) SLT006/17/00014Fondo de Investigación Sanitaria (FIS) PI09/02121, PI12/01838, PI14/00178, PI16/00603Instituto de Salud Carlos III RD16/0017/0010, RD16/0017/0003Ministerio de Economía y Competitividad MTM2015-64465-C2-1-RMinisterio de Sanidad, Política Social e Igualdad, Plan Nacional Sobre Drogas (PNSD) (2012I054National R+D+I and funded by the Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (FEDER) grant Juan Rodes JR 16/00020Suport Grups de Recerca AGAUR-Gencat 2017 SGR 316, 2017 SGR 530
6 · The paper itself

Abstract

Major depression disorder (MDD) is the most prevalent psychiatric comorbid condition in cocaine use disorder (CUD). The comorbid MDD might be primary-MDD (CUD-primary-MDD) or cocaine-induced MDD (CUD-induced-MDD), and their accurate diagnoses and treatment is a challenge for improving prognoses. This study aimed to assess the tryptophan/serotonin (Trp/5-HT) system with the acute tryptophan depletion test (ATD), and the kynurenine pathway in subjects with CUD-primary-MDD, CUD-induced-MDD, MDD and healthy controls. The ATD was performed with a randomized, double-blind, crossover, and placebo-controlled design. Markers of enzymatic activity of indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase, kynurenine aminotransferase (KAT) and kynureninase were also established. Following ATD, we observed a decrease in Trp levels in all groups. Comparison between CUD-induced-MDD and MDD revealed significant differences in 5-HT plasma concentrations (512 + 332 ng/mL vs. 107 + 127 ng/mL,

Indexed as

cocaine use disorderkynurenineprimary/substance-induced depressionserotonintryptophan

Identifiers

PMID33352710
PMCPMC7766966
OpenAlexW3117763078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.